Market capitalization | $88.78m |
Enterprise Value | $-33.41m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.24 |
P/B ratio (TTM) P/B ratio | 0.74 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-160.94m |
Free cash flow (TTM) Free cash flow | $-136.71m |
Cash position | $140.53m |
As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.
4 Analysts have issued a AlloVir Inc forecast:
4 Analysts have issued a AlloVir Inc forecast:
Mar '24 |
+/-
%
|
||
Turnover | - - |
-
|
|
Gross income | - - |
-
|
|
EBITDA | -161 -161 |
5%
5%
|
EBIT (operating result) EBIT | -161 -161 |
6%
6%
|
Net profit | -180 -180 |
8%
8%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.
Head office | United States |
CEO | Diana Brainard |
Employees | 112 |
Founded | 2013 |
Website | www.allovir.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.